Yes, Agenus maintains a controlling ownership stake and acts as a major institutional shareholder in MiNK Therapeutics Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on invariant natural killer T cell therapies. Agenus retains substantial equity shares valued in the multi-millions, exercising strategic oversight while MiNK operates as a specialized subsidiary within the broader corporate ecosystem.